Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia - Wikidata - awgldk - TriplyDB

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia

http://www.wikidata.org/entity/Q28240713

about

Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens A meta-analysis of multiple matched copy number and transcriptomics data sets for inferring gene regulatory relationships.Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.A critical role for the NFkB pathway in multiple myeloma.Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice.RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.Targeting TRAF3 Downstream Signaling Pathways in B cell Neoplasms.Frequent down regulation of the tumor suppressor gene a20 in multiple myeloma.Investigating inter-chromosomal regulatory relationships through a comprehensive meta-analysis of matched copy number and transcriptomics data sets Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities.Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice.t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth.The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development.Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.TRAF molecules in cell signaling and in human diseases Candidate genes of Waldenström's macroglobulinemia: current evidence and research.Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma.Expression and function of a novel isoform of Sox5 in malignant B cells.Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance.Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation.Molecular pathogenesis of Waldenstrom's macroglobulinemia.Genetic factors and pathogenesis of Waldenström's macroglobulinemia.Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models Novel treatment options for Waldenström macroglobulinemia Waldenström macroglobulinemia: from biology to treatment.Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.

P2860

Q26853280-5222B701-D6EB-404C-812E-E0C647F590CA Q27314737-5B5F9E65-BD8E-4E6B-9457-814D9DDFD38A Q28290236-2787418E-F7F4-4B1E-8A1F-E22084DFB657 Q30299913-E772C9C6-230F-4E1D-BD89-E73F24818D46 Q30426162-10B78E14-FE1B-41C2-AF66-A44AE73CC8F5 Q30844284-7729941F-7BCE-4083-9804-23B7F9D38F1F Q33768000-88D39715-7F4C-450E-8713-7C17CD72D287 Q33869257-273022C8-6FC7-4AFC-BA06-FC129C41DBE2 Q34165181-0C657649-2437-4039-AC9D-0C4E4D7710E3 Q34210005-87568E61-38FE-4EEB-A613-C97A7390B9BC Q34234115-3944EBC3-B4AA-47E2-91A6-0DD1C071325E Q34446744-237B5B81-22FE-4866-84BC-A66E0144F695 Q34519192-D18B0672-93D0-445A-98A3-A59696498B6D Q34749424-94B52100-4D74-414F-A720-D403DA7B69ED Q34870566-1BEFF20F-D9A9-4D7A-820F-397266323547 Q34974058-9CA00041-E1BD-41CA-8A6B-B6E9A94D5324 Q35019194-D113DCAD-1873-4839-B9AE-8D793C5C5997 Q35575662-7F44CD7F-4318-4D90-B78D-6B67673BD471 Q35598382-F99C807C-BCF6-4EB0-ADCD-8F80C0D002E5 Q35845694-2FF584F2-3DA9-45F9-8F51-8BFBBD1BB1B8 Q35926049-5F50BA43-9132-4739-B093-1576B856A4A5 Q36208548-BD022D80-BDC6-4CFF-A6FD-763B5630BE00 Q36395591-79EA553F-69BE-4AED-8B17-DFF5CFA8A82F Q36485370-B330847A-F549-4D22-AD92-06243891F94D Q36540685-4FB4AD4E-366D-4921-9573-60AB423B9B89 Q36862542-03D0510D-06B8-4A58-821D-FEB7DFB90820 Q36972287-A96D4298-46A5-44A8-A8EC-EFB76751D6C1 Q37074275-83ECB552-E1FF-4F4E-A527-912DFC956D0A Q37621361-D062B161-D9FE-4484-BC3F-CAA12F2D56CD Q37626733-E156620D-637D-47AB-A91C-C52BD38EFD5C Q37630211-1BECBD9B-DA0F-4089-9983-0E60DBBED3A7 Q37901235-64154977-738C-4A83-92D2-7B6E9D964403 Q38024773-2EE0DD37-3206-46FC-810D-40F551BC8638 Q38125430-FE299E81-8929-4557-ABBB-E50BDA38FEFA Q38150849-EA720100-19D4-41D6-81D6-593C13D69069 Q38167433-D8F0E58E-D17A-40B0-A322-CFDB424275D4 Q38176969-5AD988DB-8FD5-4462-A3C6-9068FB11D512 Q38760522-BD9F5C6A-A7C4-48D0-8FFE-94BAF135BF98 Q38819164-CF94BF7F-6688-43FD-9737-759F57DDD2BD Q38970612-31CC81C9-A8B4-4C9D-B7CF-7BD882CE4B2F

P2860

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia

http://www.wikidata.org/entity/Q28240713

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Identification of copy number ...... aldenstrom's macroglobulinemia

@ast

Identification of copy number ...... aldenstrom's macroglobulinemia

@en

Identification of copy number ...... aldenstrom's macroglobulinemia

@nl

type

label

Identification of copy number ...... aldenstrom's macroglobulinemia

@ast

Identification of copy number ...... aldenstrom's macroglobulinemia

@en

Identification of copy number ...... aldenstrom's macroglobulinemia

@nl

prefLabel

Identification of copy number ...... aldenstrom's macroglobulinemia

@ast

Identification of copy number ...... aldenstrom's macroglobulinemia

@en

Identification of copy number ...... aldenstrom's macroglobulinemia

@nl

P1433

Q28240713-C4BEE19B-045F-404A-BFE8-B135DB616066

P1476

Q28240713-D528FCBC-819E-49F6-A749-A428CFB85D05

P2093

Q28240713-141058ED-77A7-4B1B-A538-065F0E6B3147

Q28240713-1717F917-6BBE-4772-AA10-37542134BCCE

Q28240713-18E925F4-9282-4FA0-B32F-18102897BA94

Q28240713-1D9E6341-ADCA-4A0D-99B4-26D6C8394DED

Q28240713-2514D067-AA47-4759-8D90-8AEE4F231500

Q28240713-27F24114-521A-4FCB-A062-A52FDA205EEA

Q28240713-60D06C07-BA8A-44BC-99E2-503C1936FDEF

Q28240713-6CFF93B8-14F5-4C84-8BD4-C113EE589736

Q28240713-7AFBEE80-24B3-4755-9728-F6F9F4DE8AF9

Q28240713-9E09D0C2-E192-4041-A447-DC58237555DF

P2860

Q28240713-0094026C-C643-421B-A0D1-5DB9FCA94F64

Q28240713-03C22E83-B4D0-4E75-A0B0-E0D61BA8A43F

Q28240713-044F741C-D04F-452E-85BE-D88F62D4F0CC

Q28240713-079A5FC5-C983-4EEF-B0BC-4B69A7FC306E

Q28240713-1B12CFE6-039E-45D3-B6E6-E57C21DBA1A5

Q28240713-21E89A9E-91A4-4388-BBEC-20816DEFD030

Q28240713-23173DE2-EB93-4C65-984E-7D86692DE8E5

Q28240713-23E024F1-13D8-48D6-B537-6F4CDCFC3483

Q28240713-26BA10A1-48D0-4801-A384-54CE1A45707A

Q28240713-28404AF9-FC26-4D9F-A98F-AB0A7FD75791

P304

Q28240713-5A1155C5-EDC9-43CA-8666-ED88D0A35F12

P31

Q28240713-7BAFCB97-5550-4AD9-9D24-77807A5A2145

P356

Q28240713-6781C443-AFCF-459B-BCE8-9FA5576AC3FE

P407

Q28240713-DDC84387-F0ED-4AC7-B18D-E7DAA4FA5ED0

P433

Q28240713-CBBB45CB-C8C8-40AA-B8B6-8B7807783193

P478

Q28240713-AB9D22C3-3796-42CA-BBF5-1AC80FCBBDA4

P50

Q28240713-17DE884A-3121-42E2-8796-A980FA50941E

Q28240713-22F725F2-8B91-40B6-831A-E4920E667CEE

Q28240713-891C2943-0287-4F12-9FD1-4E8F0CD1E510

Q28240713-8DF7D9B4-ED19-4792-B277-0373C8A23733

Q28240713-DE366A21-9827-4BE3-A14E-0401CD6D02D6

P577

Q28240713-462276CE-85BD-4590-8611-C7F2E3486844

P698

Q28240713-F97747AE-ACCF-4C07-8C7B-04D2153C9687

P932

Q28240713-651F7E6A-92C3-4712-937B-F96437B227F3

P356

0008-5472.CAN-08-3701

P1433

Cancer Research

P1476

Identification of copy number ...... aldenstrom's macroglobulinemia

@en

P2093

A Keith Stewart

http://www.w3.org/2001/XMLSchema#string

Ahmet Dogan

http://www.w3.org/2001/XMLSchema#string

Esteban Braggio

http://www.w3.org/2001/XMLSchema#string

Feda Azab

http://www.w3.org/2001/XMLSchema#string

Irene M Ghobrial

http://www.w3.org/2001/XMLSchema#string

John Carpten

http://www.w3.org/2001/XMLSchema#string

Jonathan J Keats

http://www.w3.org/2001/XMLSchema#string

Kimberly Henderson

http://www.w3.org/2001/XMLSchema#string

Marta Chesi

http://www.w3.org/2001/XMLSchema#string

Michael Barrett

http://www.w3.org/2001/XMLSchema#string

P2860

Commitment to the B-lymphoid lineage depends on the transcription factor Pax5

A20 is a potent inhibitor of TLR3- and Sendai virus-induced activation of NF-kappaB and ISRE and IFN-beta promoter

miR-15 and miR-16 induce apoptosis by targeting BCL2

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice

MiR-15a and miR-16-1 cluster functions in human leukemia

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma

Familial Waldenstrom's macroglobulinemia

Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway

P304

3579-3588

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-08-3701

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

S. Vincent Rajkumar

Suzanne R Hayman

P577

2009-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19351844

http://www.w3.org/2001/XMLSchema#string

P932

2782932

http://www.w3.org/2001/XMLSchema#string